A team from University Hospitals Seidman Cancer Center is launching the nation's first-ever clinical trials evaluating the ...

He is a listed applicant on a patent application in relation to the use of fenofibrate for treatment of diabetic retinopathy. He holds no shares, stocks or options in any pharmaceutical company.

Cancer mortality evaluations revealed up to a 24% reduced risk between the highest and lowest blood lycopene levels, with dose-response analyses suggesting that 5-7 mg/day was within the ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...